文献速递青光眼

无滤过泡依赖的ab externo SIBS微分流管植入术治疗难治性青光眼的一年结果

One-year outcomes of stand-alone ab externo SIBS microshunt implantation in refractory glaucoma.
PubMed 文献 · Br J Ophthalmol · 2020-10-23

该研究回顾性分析85眼既往结膜下滤过手术失败、眼压未达标的青光眼患者,行丝裂霉素C辅助的ab externo SIBS微分流管单独植入术。术后1年完全成功率61.0%,条件成功率79.7%,中位眼压从术前22.0 mmHg降至13.0 mmHg,用药从4种降至0种,并发症轻微且短暂。轻度至中度病变与手术失败相关。

要点

  • 既往滤过手术失败的难治性青光眼中,SIBS微分流管1年完全成功率61.0%,条件成功率79.7%。
  • 术后1年中位眼压从22.0 mmHg降至13.0 mmHg,降眼压药物从4种降至0种。
  • 轻度至中度病变是手术失败的独立危险因素(校正HR 2.37,95%CI 1.23-4.59)。

核心结论

  • 在既往至少一次结膜下滤过手术失败的高危眼中,SIBS微分流管植入术1年随访显示合理的手术成功率,并发症相对较少。

研究设计与样本

  • 连续回顾性队列研究,纳入2015年7月至2019年4月期间接受SIBS微分流管植入术、眼压高于目标值且既往有结膜下滤过手术史的患者。
  • 共纳入79例患者85眼,术前中位眼压22.0 mmHg(IQR 18.0-29.0),使用4种(IQR 3-4)降眼压药物。

主要发现

  • 术后1年中位眼压13.0 mmHg(IQR 10.0-17.0),使用0种(IQR 0-2)降眼压药物。
  • 完全成功率为61.0%,条件成功率为79.7%。
  • 轻度至中度病变与失败相关(校正HR 2.37;95%CI 1.23-4.59)。
  • 11.8%的患者接受针刺治疗,8.2%行前房重建,7.1%行再次手术。
  • 并发症为暂时性,包括前房积血、脉络膜脱离和低眼压性黄斑病变。

关键数值与推荐

  • 完全成功定义:未使用降眼压药物;失败定义:眼压<6 mmHg伴视力丧失、眼压>17 mmHg或眼压降低<20%(未用药)。
  • 次要结局包括6-14 mmHg和6-21 mmHg阈值下的完全成功与条件成功,以及6-17 mmHg阈值下的条件成功。

临床怎么用

  • 对于既往结膜下滤过手术失败的难治性青光眼,SIBS微分流管植入术可考虑作为降低眼压并减少用药的选择。
  • 术后需监测前房积血、脉络膜脱离和低眼压性黄斑病变等暂时性并发症,部分患者可能需要针刺或再次手术。

局限性

  • 回顾性研究设计,样本量有限(85眼),随访时间仅1年,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Determine the efficacy of stand-alone implantation of the ab externo SIBS or poly(styrene-block-isobutylene-block-styrene) microshunt with mitomycin C in glaucomatous eyes, refractory to previous subconjunctival filtering surgery, over 1 year of follow-up. METHODS: Consecutive retrospective cohort of patients with intraocular pressure (IOP) above target and previous subconjunctival filtering surgery, who received the microshunt between July 2015 and April 2019. Primary outcome was a complete success, with failure defined as IOP <6 mm Hg with vision loss, >17 mm Hg or <20% reduction in IOP without medications. Secondary outcomes included thresholds of 6 to 14 mm Hg and 6 to 21 mm Hg for both complete (no medications) and qualified (with medications) success as well as qualified success for thresholds of 6 to 17 mm Hg. Risk factors for failure, IOP, medications and complications were also assessed. RESULTS: 85 eyes of 79 patients with a preoperative median IOP of 22.0 mm Hg (IQR 18.0-29.0) on four (IQR 3-4) medications were included. Postoperative median IOP was 13.0 mm Hg (IQR 10.0-17.0) on zero (IQR 0-2) medication at 1 year. 61.0% achieved complete success and 79.7% achieved qualified success. Mild-to-moderate disease was associated with failure (adjusted HR 2.37; 95% CI 1.23 to 4.59). Needling was performed in 11.8%, and 8.2% underwent anterior chamber reformation. Complications were transient, consisting of hyphaema, choroidal detachment and hypotony maculopathy, with 7.1% of patients undergoing reoperation. CONCLUSIONS: In a group of high-risk eyes that had already failed at least one subconjunctival filtering surgery, the SIBS microshunt demonstrates reasonable surgical success over 1-year follow-up, with relatively few complications.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Durr GM, Schlenker MB, Samet S, et al. One-year outcomes of stand-alone ab externo SIBS microshunt implantation in refractory glaucoma. Br J Ophthalmol. 2020. PMID: 33097520. doi:10.1136/bjophthalmol-2020-317299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。